Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Annovis Bio Inc. (NYSE: ANVS) has achieved significant milestones in its pivotal Phase 3 clinical trial for early Alzheimer's disease, with all 84 U.S. clinical sites now fully activated and enrolling patients. The late-stage clinical drug platform company reported that most sites are already treating participants, and the first group of patients has completed the 6-month treatment phase, keeping the company on schedule to deliver symptomatic data in the second half of 2026.
CEO Maria Maccecchini emphasized that the study is now 25% complete, reflecting strong execution and continued momentum toward bringing the company's lead drug candidate, buntanetap, to patients suffering from neurodegenerative diseases. The progress represents a critical step forward in developing effective therapies for Alzheimer's disease, a condition affecting millions worldwide with limited treatment options currently available.
The company's clinical development program focuses on addressing neurodegeneration in both Alzheimer's and Parkinson's diseases. Investors and stakeholders can access detailed information about the company's progress through its official newsroom at https://ibn.fm/ANVS. The trial's advancement comes at a time when the global healthcare community continues to seek breakthrough treatments for Alzheimer's, a disease characterized by progressive cognitive decline and memory loss.
Annovis Bio's platform approach to neurodegenerative diseases positions the company at the forefront of neurological drug development. The successful site activation and patient completion milestones demonstrate the company's operational capabilities in managing large-scale clinical trials across multiple geographic locations. For additional information about the company and its research programs, visit https://www.annovisbio.com.
The Phase 3 trial's progress marks an important development in the Alzheimer's treatment landscape, where successful clinical outcomes could potentially address significant unmet medical needs. The company's systematic approach to trial execution, evidenced by the 25% completion rate and maintained timeline for data delivery in 2026, provides confidence in the program's management and potential for success in bringing new therapeutic options to patients.